Viewing nowCombinationNesinamet Extended-Release Tablets 12.5/500 mg (Alogliptin, Metformin Hydrochloride)
Metformin Hydrochloride 500mg · Alogliptin Benzoate 17mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.

MFDS item code 202302754 · Approved 2023.09.14 · Insurance code 693904010
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is adjunctively administered with dietary and exercise therapy to help control blood sugar levels in patients with type 2 diabetes using alogliptin and metformin together. It effectively manages blood sugar levels to aid in diabetes treatment.
For antidiabetic therapy, the dose of this drug should be adjusted according to efficacy and tolerability, without exceeding the maximum recommended daily doses of each component: 25mg of alogliptin and 2000mg of extended-release metformin hydrochloride. The initial dose of this drug should be determined based on the patient’s current treatment regimen. This drug should be taken once daily, preferably with the evening meal, to reduce gastrointestinal adverse reactions associated with metformin use, and the dose of metformin hydrochloride should be increased gradually. Take 1 tablet of this drug 25/1000mg extended-release tablets once daily. Patients taking this drug 12.5/1000mg or 12.5/500mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin The initial dose of this drug is a total daily dose of alogliptin 25mg and metformin hydrochloride 1000mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of 2000mg to reduce gastrointestinal adverse reactions from metformin. 2. Patients treated with metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of alogliptin 25mg and the patient’s current dose of metformin hydrochloride, based on the patient’s current treatment regimen. - For patients who cannot achieve adequate glycemic control with metformin and pioglitazone combination therapy or metformin and insulin combination therapy, the initial dose of this drug is a total daily dose of alogliptin 25mg; the initial dose of metformin hydrochloride should be determined taking into account the patient’s blood glucose level and current dose. When this drug is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see section 5. General Precautions under Precautions for Use). - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if needed. - Substitution for combination therapy with alogliptin and metformin When switching from combination therapy with alogliptin and metformin to this drug, the dose of this drug should correspond to the patient’s current doses of alogliptin and metformin hydrochloride. Patients with Renal Impairment Because dose adjustment is required according to renal function, assessment of renal function is recommended before starting this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment (creatinine clearance ≥60mL/min). In patients with moderate renal impairment (CKD stage 3A) whose creatinine clearance is ≥45mL/min and <60mL/min, and who do not have other conditions that may increase the risk of lactic acidosis, this drug may be used with dose adjustment as follows: - The daily dose of alogliptin is 12.5mg. - The starting dose of extended-release metformin hydrochloride is 500mg or 750mg once daily, and the maximum daily dose is 1000mg. If creatinine clearance falls below 45mL/min, this drug should be discontinued immediately.
This medication contains two components, Metformin Hydrochloride and Alogliptin, which assist in blood sugar control. However, Metformin Hydrochloride may cause a dangerous condition known as severe lactic acidosis, so it should not be used in patients with impaired kidney function or acute diseases. Additionally, individuals who have experienced allergic reactions to this medication or similar drugs should not take it. Patients with moderate to severe kidney dysfunction, acute heart failure, or cardiovascular collapse should also avoid this medication. When undergoing radiological examinations with iodine contrast agents, this medication must be withheld for a certain period before and after the examination, and it should be resumed only after confirming normal kidney function. This medication is not suitable for patients with type 1 diabetes or those experiencing diabetic ketoacidosis. Patients with severe infections, significant trauma, or who are preparing for surgery may require insulin therapy instead of this medication. Patients with liver dysfunction or those who consume excessive alcohol should avoid using this medication. This medication carries a risk of hypoglycemia, so caution is advised when irregular meals, intense physical activity, or concurrent use with other antidiabetic agents occurs. During treatment, if symptoms such as pancreatitis, severe allergic reactions, liver dysfunction, severe joint pain, or skin blistering occur, consult a doctor immediately. Additionally, do not crush or chew the tablets; swallow them whole, although the tablet shell may appear in feces, which is normal. This medication is not recommended for women during pregnancy or breastfeeding; particularly, it is safest to avoid use while breastfeeding. Elderly patients should undergo regular kidney function tests, as they are at higher risk of impairment, and dosage adjustments may be necessary. In case of overdose, prompt medical care and any necessary treatment are required, and the metformin component can be partially removed through hemodialysis. Lastly, it is advisable to avoid alcohol consumption during the course of this medication, and report any blood sugar fluctuations or abnormal symptoms to healthcare professionals immediately.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air, and it is best stored at room temperature between 1 to 30 degrees Celsius. Proper storage helps maintain the drug's efficacy and prevents degradation.
Pale yellow oval-shaped extended-release film-coated tablets
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationMetformin Hydrochloride 500mg · Alogliptin Benzoate 17mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
Alogliptin Benzoate 17mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
Alogliptin Benzoate 17mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Celltrion Healthcare Co., Ltd.
Alogliptin Benzoate 17mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Alogliptin Benzoate 34mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Alogliptin Benzoate 17mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
CombinationAlogliptin Benzoate 17mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
CombinationAlogliptin Benzoate 17mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.